Diversity, Equity, & Inclusion Awards

Applications Open June 1

In June 2020, ASGCT made a commitment to promoting justice and equity in gene and cell therapy research. These new funding opportunities included the creation of the Society’s first two fellowship awards, which aim to support underrepresented populations, including minorities, in gene and cell therapy, and the introduction of an award in support of research on conditions disproportionately impacting minority populations.

Funding Opportunities

Underrepresented Minority Fellowship Award in Gene and Cell Therapy for Oncology

This $100,000 award supports one ASGCT member from an underrepresented minority population as defined by the NIH in a postdoctoral or early-stage investigator with a fellowship in gene or cell therapy-related research for an oncology indication for one year, from November 2023 to December 2024.

Underrepresented Population Fellowship Award in Gene and Cell Therapy for Any Indication

This  $100,000  award will support one  ASGCT member from an underrepresented group in the scientific workforce as defined by the NIH through a  postdoctoral  or early-stage investigator  fellowship  in  any  gene or cell  therapy-related research  for  one year, from November 2023 to December 2024. 

Award for Research on Conditions Disproportionately Affecting Minorities

This  $50,000  award will  support one  ASGCT member in  gene or cell  therapy-related research  for  conditions disproportionately affecting minorities  for one year, from  November  2023  to  December 2024. ASGCT is committed to addressing disparities in current treatment pipelines,  specifically  in the  level and breadth of research surrounding conditions that primarily affect minority populations.

Thank You to Our Sponsors

We greatly appreciate these supporters of the DEI awards.


Register for the 27th Annual Meeting

May 7-11, 2024 | Baltimore, MD

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.